Expired activity
Please go to the PowerPak
homepage and select a course.
The Pharmacist’s Role in Managing Disease-Modifying Therapies in Adults With Multiple Sclerosis
This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and Spire Learning and supported by an independent educational grant provided by Biogen Inc., Novartis, and Sanofi Genzyme.
FACULTY
Jacquelyn L. Bainbridge, PharmD, BS Pharm, FCCP, MSCS (Biography)
Professor, Department of Clinical Pharmacy and Neurology
Skaggs School of Pharmacy and Pharmaceutical Sciences
Anschutz Medical Campus
University of Colorado
Aurora, Colorado
Matthew C. Bainbridge
Undergraduate Student
Department of Psychology and Neuroscience
University of Colorado, Denver
Denver, Colorado
Sarah N. Fischer, PharmD
Clinical Neurology Research Fellow
Skaggs School of Pharmacy and Pharmaceutical Sciences
Anschutz Medical Campus
University of Colorado
Aurora, Colorado
FINANCIAL DISCLOSURE
Jaquelyn L. Bainbridge, PharmD, BS Pharm, FCCP, MSCS, hereby states that she has the following relevant affiliation or financial relationship or relationship to products or devices with a commercial interest related to the content of this activity to disclose:
Consultant/Advisory Board – Genentech, Inc
Matthew C. Bainbridge has indicated that he has no financial relationships or relationships to products or devices with any commercial interest related to the content of this activity.
Corresponding author, Sarah N. Fischer, PharmD, has indicated that she has no financial relationships or relationships to products or devices with any commercial interest related to the content of this activity.
The following reviewer, Steven Kheloussi, PharmD, has indicated that he has no financial relationships or relationships to products or devices with any commercial interest related to the content of this activity.
Susanne Batesko, RN, BSN, Aisha Cobbs, PhD, Robin Carrino, Mairead Early, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE)/Spire Learning continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
ACCREDITATION STATEMENTS
PHARMACY
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-9999-19-021-H01-P
Credits: 1.0 hours (0.10 ceu)
Type of Activity: Knowledge
Media: Internet
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 60 minutes
Published:
May 31, 2019
Expires:
May 31, 2020
TARGET AUDIENCE
This accredited activity has been designed for pharmacists with an interest in the management of multiple sclerosis.
How to Earn Credit
During the period May 31, 2019, through May 31, 2020, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the posttest and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Grade Exam at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
Goal
To educate pharmacists about MS pathophysiology and the new American Academy of Neurology recommendations for the use of disease-modifying therapies (DMTs) in adults.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- DESCRIBE the pathophysiological mechanisms that contribute to multiple sclerosis (MS)
- EVALUATE the safety and efficacy of available disease-modifying therapies
- EMPLOY care coordination strategies that emphasize multidisciplinary collaboration and advocacy for individuals with MS
- DEFINE the pharmacist's role in providing drug management and administrative support to people receiving MS therapy and their providers
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, Spire Learning, Biogen Inc., Novartis, and Sanofi Genzyme. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without an evaluation of their patients’ conditions and current medications, including the identification of possible contraindications regarding the dangers of use and a review of any applicable manufacturer’s product information, as well as a comparison with the recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer’s package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.
